Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial
Descripción general
Resumen del artículo
In a study of patients with type 2 diabetes and chronic kidney disease, combining finerenone and empagliflozin led to better kidney function improvement compared to either drug alone, across a range of baseline kidney risk levels. However, the study only followed participants for six months and further long-term research is needed to confirm lasting benefits and safety.
Explícamelo como si tuviera cinco años
Combining two diabetes medications (finerenone and empagliflozin) may be better than using either one alone for improving kidney function in people with type 2 diabetes and chronic kidney disease, regardless of their initial kidney risk level.
Posibles conflictos de intereses
The study was funded by Bayer AG, the manufacturer of finerenone. Several authors reported financial ties to pharmaceutical companies, including Bayer, involved in diabetes and kidney disease treatments.
Limitaciones identificadas
Explicación de la calificación
This is a well-designed study with a large sample size and important clinical implications. Although the short follow-up duration and strict inclusion criteria limit generalizability to some extent, the findings about consistent benefits across different levels of kidney risk remain valuable.
Conviene saber
Este es el análisis de Starter. Paperzilla Pro verifica cada cita, investiga los antecedentes de los autores y las fuentes de financiación, y utiliza razonamiento avanzado con IA para ofrecer información más exhaustiva.
Explorar Pro →